NCT06826989

A Study of MK-8527 in Healthy Adult Participants (MK-8527-013)

A Phase 1 Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]MK-8527 in Healthy Adult Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: Merck Sharp & Dohme LLC · Industry
• Sex: Male
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The goal of this study is to learn how \[14C\]MK-8527 moves through a healthy person's body over time. Researchers will study how \[14C\]MK-8527 is absorbed by the body, broken down by the body, and how it leaves the body.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	[14C]MK-8527	Oral Dose

Timeline

• Start date: 2025-03-19
• Primary completion: 2025-06-04
• Completion: 2025-06-04
• First posted: 2025-02-14
• Last updated: 2025-06-11

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study